Biopharma Credit PLC - New York-based life sciences debt investment trust - Company’s investment manager, Pharmakon Advisors, notes the announcement made by Pfizer Inc on Wednesday about acquisition of Global Blood Therapeutics for $5.4 billion. BioPharma had $132.5 million investment in Global Blood Therapeutics in a senior secured loan which has been prepaid following the acquisition. The senior secured loan was invested through three different tranches. In total the company received $175.4 million, including $42.9 million of accrued interest, paydown, prepayment and make-whole fees, realising an internal rate of return of 28%.

Current stock price: 85.54 pence

12-month change: up 19%

Copyright 2022 Alliance News Limited. All Rights Reserved.